Navigation Links
NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
Date:11/12/2009

FT. MYERS, Fla., Nov. 12 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference being held November 17-18, 2009, at the St. Regis, New York Hotel in New York City. The conference will showcase public and private life sciences and biotech companies. Senior executives of attending companies will make presentations to portfolio managers and analysts on their business strategy and outlook. One-on-one meetings with interested parties will also be arranged during the three-day conference.

NeoGenomics is scheduled to present on Wednesday, November 18th at 9:30 AM EST in the Library Room on the second floor of the hotel. A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/lz6/ngnm.ob/. A PowerPoint presentation and a link to the webcast can also be accessed through the investor relations section of the NeoGenomics website at http://www.neogenomics.com at the time of the conference. The webcast will be available for three months.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.

For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.

SOURCE NeoGenomics, Inc.


'/>"/>
SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoGenomics to Present at the Rodman & Renshaw Healthcare Investment Conference on September 10, 2009
2. NeoGenomics Reports Second Quarter 2009 Results
3. NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results
4. NeoGenomics Schedules its Q4 and Full Year 2008 Earnings Release for March 5, 2009
5. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
6. NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008
7. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
8. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
9. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Viron to Present Data from Phase II Trial at American Heart Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):